Biochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial brachytherapy monotherapy.
Affiliation
The Christie NHS Foundation Trust, Manchester, UK. Electronic address: anna.tran@christie.nhs.uk.Issue Date
2013-07-09
Metadata
Show full item recordAbstract
Routine use of I-125 interstitial brachytherapy (BT) alone in intermediate risk (IR) prostate cancer is controversial. It is often combined with external beam radiotherapy (EBRT). The biochemical outcome of a large cohort of only IR disease treated with BT monotherapy is reported.Citation
Biochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial brachytherapy monotherapy. 2013: Radiother OncolJournal
Radiotherapy and OncologyDOI
10.1016/j.radonc.2013.05.030PubMed ID
23849172Type
ArticleLanguage
enISSN
1879-0887ae974a485f413a2113503eed53cd6c53
10.1016/j.radonc.2013.05.030